KR880700070A - 비루스 왁찐 - Google Patents

비루스 왁찐

Info

Publication number
KR880700070A
KR880700070A KR870700280A KR870700280A KR880700070A KR 880700070 A KR880700070 A KR 880700070A KR 870700280 A KR870700280 A KR 870700280A KR 870700280 A KR870700280 A KR 870700280A KR 880700070 A KR880700070 A KR 880700070A
Authority
KR
South Korea
Prior art keywords
virus
glycoprotein
wax
gastric rabies
herpes
Prior art date
Application number
KR870700280A
Other languages
English (en)
Other versions
KR950000887B1 (ko
Inventor
이이 포스트 레너드
아아르 톰센 다렐
Original Assignee
케네스 엠 사이러스
디 엎죤 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케네스 엠 사이러스, 디 엎죤 캄파니 filed Critical 케네스 엠 사이러스
Publication of KR880700070A publication Critical patent/KR880700070A/ko
Application granted granted Critical
Publication of KR950000887B1 publication Critical patent/KR950000887B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)

Abstract

내용 없음

Description

비루스 왁찐
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 분비 당단백질을 암호화하는 유전자에 대한 삭제부분을 갖고 있는 적절하게 무력해진 비루스로 이루어져 있으며, 왁찐 비루스와 그의 야생형 프로제니터 (progenitor) 비루스와의 혈청학적인 구별을 가능하게끔 해주는 헤르페스 비루스 왁찐.
  2. 제1항에 있어서, 비루스가 위광견병 비루스, 마레크병 비루스 및 전염병 우형 비(鼻) 기관염 비루스로 이루어진 군으로 부터 선택되는 왁찐.
  3. 제1항에 있어서, 비루스가 위광견병 비루스인 왁찐.
  4. 제1항에 있어서, 비루스가 위광견병 비루스이고 분비 당단백질이 당단백질 X인 왁찐.
  5. 분비 당단백질을 암호화하는 적어도 하나의 유전자에 대한 삭제부분을 갖고 있는 헤르페스비루스.
  6. 제5항에 있어서, 위광견병 비루스, 바레크병 비루스 및 전염성 우형 비기관염 비루스로 이루어진 군으로 부터 선택된 헤르페스비루스.
  7. 제5항에 있어서, 헤르페스 비루스가 위광견병 비루스인 헤르페스 비루스.
  8. 제7항에 있어서, 분비 당단백질이 당단백질 X인 헤르페스 비루스.
  9. 제8항에 있어서, 비루스가 기능성 티미딘 카이나제를 생산하지 않는 헤르페스 비루스.
  10. 비루스에 감염되기 쉬운 동물에게, 야생형 프로제니터 비루스의 항원을 암호화하는 적어도 하나의 유전자에 대한 삭제 부분을 갖고 있는 비루스로 이루어진 왁찐을 접종한 후, 동물을 희생시키지 않고서도 그와 같은 왁찐 주사를 맞은 동물과 독성 비루스에 감염된 동물을 혈청학적으로 구별하는 것으로 구성되는, 비루스에 감염된 동물과 이 비루스에 대항하는 왁찐주사를 맞은 동물을 구별하기 위한 방법.
  11. 제10항에 있어서, 비루스가 헤르페스 비루스인 방법.
  12. 제10항에 있어서, 비루스가 위광견병 비루스, 마레크병 비루스 및 전염성 우형 비 기관염 비루스로 이루어진 군으로부터 선택되는 방법.
  13. 제10항에 있어서 비루스가 위광견병 비루스인 방법.
  14. 제20항에 있어서, 항원이 당단백질인 방법.
  15. 제10항에 있어서, 항원이 분비 당단백질인 방법.
  16. 제10항에 있어서, 비루스가 위광견병 비루스이고 당단백질이 당단백질 X인 방법.
  17. 항원을 암호화하는 유전자 속에 면역 반응을 일으킬 수 있는 이종(異種) 폴리펩티드를 암호화하는 DNA 서열이 삽입되어 있는 적절하게 무력해진 비루스로 이루어진 다가 왁찐.
  18. 제17항에 있어서, 비루스가 헤르페스 비루스이고 항원이 분비 당단백질인 왁찐.
  19. 제17항에 있어서, 비루스가 위광견병 비루스, 마레크병 비루스, 전염성 비 기관염 비루스로 이루어진 군으로 부터 선택되는 왁찐.
  20. 제18항에 있어서, 헤르페스비루스가 위광견병 비루스이고 분비 당단백질이 당단백질 X인 왁찐.
  21. 제20항에 있어서, 면역 반응을 일으킬 수 있는 폴리펩티드가 전달성 위장염 비루스 또는 돼지의 미소비루스로 부터의 폴리펩티드로 이루어진 군으로 부터 선택되는 왁찐.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870700280A 1985-07-29 1986-06-17 프로제니터 비루스 왁찐 조성물, 이의 제조방법, 및 이를 사용하여 비루스에 감염된 동물과 왁찐 주사를 맞은 동물을 구별하기 위한 방법 KR950000887B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76013085A 1985-07-29 1985-07-29
US760,130 1985-07-29
US760130 1985-07-29
PCT/US1986/001322 WO1987000862A1 (en) 1985-07-29 1986-06-17 Virus vaccine

Publications (2)

Publication Number Publication Date
KR880700070A true KR880700070A (ko) 1988-02-15
KR950000887B1 KR950000887B1 (ko) 1995-02-03

Family

ID=25058182

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870700280A KR950000887B1 (ko) 1985-07-29 1986-06-17 프로제니터 비루스 왁찐 조성물, 이의 제조방법, 및 이를 사용하여 비루스에 감염된 동물과 왁찐 주사를 맞은 동물을 구별하기 위한 방법

Country Status (18)

Country Link
US (1) US4810634A (ko)
EP (1) EP0231209B1 (ko)
JP (2) JP2559384B2 (ko)
KR (1) KR950000887B1 (ko)
CN (1) CN1018845B (ko)
AT (1) ATE60799T1 (ko)
AU (1) AU591145B2 (ko)
CA (1) CA1275625C (ko)
DE (1) DE3677494D1 (ko)
DK (1) DK170948B1 (ko)
ES (1) ES2001752A6 (ko)
FI (1) FI871362A0 (ko)
HK (1) HK32696A (ko)
IE (1) IE59087B1 (ko)
NO (1) NO301284B1 (ko)
PH (1) PH25776A (ko)
WO (1) WO1987000862A1 (ko)
ZA (1) ZA865277B (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041536A (en) * 1984-05-02 1991-08-20 The Upjohn Company Pseudorabies virus (PRV) gene
US5275934A (en) * 1985-07-29 1994-01-04 The Upjohn Company Method of detecting viral infection in vaccinated animals
US5128128A (en) * 1985-07-29 1992-07-07 The Upjohn Company Virus vaccine
US5763269A (en) * 1985-09-06 1998-06-09 Syntro Corporation Recombinant infectious bovine rhinotrocheitis virus
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US5047237A (en) * 1985-09-06 1991-09-10 Prutech Research And Development Partnership Attenuated pseudorabies virus having a deletion of at least a portion of a gene encoding an antigenic, nonessential protein, vaccine containing same and methods of identifying animals vaccinated with the vaccine
EP0238618A1 (en) * 1985-10-04 1987-09-30 The Upjohn Company Pseudorabies virus protein
US5352575A (en) * 1985-10-04 1994-10-04 The Upjohn Company Pseudorabies virus protein
US5593873A (en) * 1986-01-27 1997-01-14 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
EP0256092B1 (en) * 1986-01-27 1998-04-08 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
US6172186B1 (en) 1986-03-26 2001-01-09 Pharmacia & Upjohn Company Pseudorabies virus protein
FR2601689B1 (fr) * 1986-07-17 1992-10-16 Syntro Corp Herpes virus attenues, herpes virus qui renferment de l'adn etranger codant pour une sequence d'amino-acides, et vaccins les contenant
US5004693A (en) * 1986-07-18 1991-04-02 E. I. Du Pont De Nemours And Company Pseudorabies virus recombinants and their use in the production of proteins
US5037742A (en) * 1986-07-18 1991-08-06 E. I. Du Pont De Nemours And Company Pseudorabies virus recombinants and their use in the production of proteins
ES2055687T3 (es) * 1986-10-08 1994-09-01 Upjohn Co Vacuna de virus.
JPH02502693A (ja) * 1987-03-19 1990-08-30 サイナーゲン，インコーポレーテッド 外来ｄｎａ発現産物の家禽類への導入のためのウイルスベクター系およびその作製方法
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5783195A (en) * 1991-07-18 1998-07-21 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus S-IBR-052 and uses thereof
DE3854190T2 (de) * 1987-07-27 1996-03-28 Syntro Corp Attenuierte herpesviren, herpesviren, die für eine aminosäuresequenz kodierende fremde dns beeinhalten und sie enthaltende impfstoffe.
US5128129A (en) * 1987-11-03 1992-07-07 Novagene Inc. Infectious bovine rhinotrachetis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
US4992051A (en) * 1987-11-03 1991-02-12 Novagene, Inc. Infectious bovine rhinotracheitis virus mutants, methods for the production of same and methods for the use of same
US5069901A (en) * 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
JP2583115B2 (ja) * 1988-09-10 1997-02-19 財団法人化学及血清療法研究所 組換えマレック病ウイルスおよびその製法
US5122447A (en) * 1989-01-23 1992-06-16 Iowa State University Research Foundation, Inc. Method of detecting pseudorabies virus specific serum antibody by use of a universal diagnostic antigen
US5240703A (en) * 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
WO1993002104A1 (en) * 1991-07-18 1993-02-04 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
US5874279A (en) * 1991-07-18 1999-02-23 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
WO1993024147A1 (en) * 1992-05-29 1993-12-09 Smithkline Beecham Corporation Lecithin adjuvanted modified live virus vaccines
TW289731B (ko) * 1992-07-09 1996-11-01 Akzo Nv
AU4702293A (en) * 1992-07-30 1994-03-03 Akzo Nobel N.V. Vector vaccines of recombinant feline herpesvirus
EP0619840A1 (en) * 1992-10-06 1994-10-19 Akzo Nobel N.V. Pseudorabies virus vaccine
US5738854A (en) * 1992-10-06 1998-04-14 Akzo Nobel N.V. Pseudorabies virus vaccine
ES2074965B1 (es) * 1994-01-31 1996-05-01 Hipra Lab Sa Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
EP1985705A3 (en) * 1994-06-17 2008-12-10 Instituut voor Dierhouderij en Diergezondheid Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections
US6284251B1 (en) 1996-02-26 2001-09-04 Kansas State University Research Foundation BHV-1 gene-deleted virus vaccine
GB0126047D0 (en) * 2001-10-30 2001-12-19 Univ Cambridge Tech Therapeutic molecules
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
CA2942166A1 (en) 2014-03-03 2015-09-11 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
WO2017106736A1 (en) * 2015-12-18 2017-06-22 Louisiana State University Research & Technology Foundation Pseudorabies virus (prv) vector expressing heterologous polypeptides
WO2020093984A1 (en) * 2018-11-06 2020-05-14 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition against avian influenza virus h5 subtype

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
NL8303501A (nl) * 1983-10-12 1985-05-01 Centraal Diergeneeskundig Inst Deletiemutant van een herpesvirus en vaccin, dat dit virus bevat.
US4514497B1 (en) * 1983-12-30 1998-02-24 Novagene Inc Modified live pseudorabies viruses
US4703011A (en) * 1985-11-12 1987-10-27 Novagene, Inc. Thymidine kinase deletion mutants of bovine herpesvirus-1
US4711850A (en) * 1986-01-28 1987-12-08 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same

Also Published As

Publication number Publication date
EP0231209B1 (en) 1991-02-06
AU5994886A (en) 1987-03-05
FI871362A (fi) 1987-03-27
CN1018845B (zh) 1992-10-28
DE3677494D1 (de) 1991-03-14
ZA865277B (en) 1987-03-25
US4810634A (en) 1989-03-07
NO871313L (no) 1987-03-27
IE861996L (en) 1987-01-29
JP2559384B2 (ja) 1996-12-04
CN86105450A (zh) 1987-03-04
EP0231209A1 (en) 1987-08-12
DK157087A (da) 1987-03-27
KR950000887B1 (ko) 1995-02-03
JPS63500449A (ja) 1988-02-18
NO301284B1 (no) 1997-10-06
JP2738524B2 (ja) 1998-04-08
ATE60799T1 (de) 1991-02-15
ES2001752A6 (es) 1988-06-16
DK170948B1 (da) 1996-03-25
DK157087D0 (da) 1987-03-27
PH25776A (en) 1991-10-18
FI871362A0 (fi) 1987-03-27
JPH08333279A (ja) 1996-12-17
IE59087B1 (en) 1994-01-12
WO1987000862A1 (en) 1987-02-12
CA1275625C (en) 1990-10-30
AU591145B2 (en) 1989-11-30
NO871313D0 (no) 1987-03-27
HK32696A (en) 1996-03-01

Similar Documents

Publication Publication Date Title
KR880700070A (ko) 비루스 왁찐
ATE498006T1 (de) Rekombinantes herpesvirus aus truthähnen und seine verwendungen
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
Collen et al. Heterotypic recognition of foot-and-mouth disease virus by cattle lymphocytes
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
KR890014740A (ko) 재조합 마렉병 비루스 및 백신
Morein et al. Protein subunit vaccines of parainfluenza type 3 virus: immunogenic effect in lambs and mice
KR920021706A (ko) 제조 합형 아비폭스 바이러스, 이 바이러스에 의하여 감염된 세포의 배양, 이 바이러스로부터 유도된 가금용 왁찐
HUP0000356A2 (hu) Hibás vírusgenomokon alapuló rekombináns vektorok és alkalmazásuk vakcinák kialakítására
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
ATE102650T1 (de) Mutanten des infektioesen bovinen rhinotracheitisvirus, vakzine die sie enthalten, verfahren zu ihrer herstellung und ihrer verwendung.
WO1994000586A3 (fr) Mutants et vaccins du virus de la rhinotracheite infectieuse bovine
DE68926274D1 (de) Rekombinante HBsAg Hybridpartikel, die morphologische Eigenschaften von HBsAg-Antigen haben und eine immunogene Sequenz enthalten, die neutralisierende Antikörper gegen HIV induziert oder die von diesen Antikörpern erkannt ist, Nukleotide Sequenzen, die diese Partikel codieren und sie enthaltende Impfstoffe
ATE180278T1 (de) Auf dem gb-protein des marek's disease virus (mdv) basierende, rekombinante impfstoffe
DE69203950T2 (de) Rekombinanter Impfstoff gegen Marek's Krankheit.
Sheppard Viral vectors for veterinary vaccines
DK0606452T3 (da) Vektorvacciner fra rekombinant katteherpesvirus
Bridges et al. The characterization of equine herpes virus-1-infected cell polypeptides recognized by equine lymphocytes.
Tikhonenko Prospects and achievements in the development of genetically engineered antiviral vaccines.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060106

Year of fee payment: 12

EXPY Expiration of term